PDS Biotechnology Corporation
Pagina dedicata companiei PDS Biotechnology Corporation listata cu simbolul US.PDSB
Descriere companie[edit | ]
PDS Biotechnology Corporation (https://www.pdsbiotech.com) is a clinical-stage immunotherapy company. The Company is focused on developing a growing pipeline of cancer immunotherapy candidates and infectious disease vaccine candidates designed to overcome the limitations of immunotherapy technologies. It owns Versamune, a T-cell activating platform designed to train the immune system to destroy disease. Its lead product candidate, PDS0101, which combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products is all administered by subcutaneous injection. DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on agonist antigens from the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Grafic actiuni companie[edit | ]